Indofarma (Persero) Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Indofarma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Novartis India Limited
sales of 8.08 billion Indian Rupees [US$121.49 million]
of which 81%
Shenzhen Neptunus Interlong Bio-technique Co Ltd
(759.11 million Chinese Renmimbi [US$120.17 million]
of which 57%
was Manufacturing & selling medicine product), and
Jiangxi Fuxiang Pharmaceutical Co Ltd
based in China
(763.68 million Chinese Renmimbi [US$120.89 million]
of which 100%
was Pharmaceutical manufacturing industry).
During the year ended December of 2016, sales at
Indofarma (Persero) Tbk PT were 1.67 trillion Indonesian Rupiahs (US$120.58 million).
increase of 3.3%
versus 2015, when the company's sales were 1.62 trillion Indonesian Rupiahs.
This was the fourth straight year of sales growth at Indofarma (Persero) Tbk PT.